http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20020068262-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2000-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20020068262-A |
| titleOfInvention | Method for validating/invalidating target(s) and pathways |
| abstract | As a method of determining the existence of a correlation between a function of a disease or condition and a gene or mRNA that encodes a target polypeptide suspected to be related to the disease or condition,n n n Proximity between the target gene and its corresponding mRNA, 3 'and 5' intron-exon boundaries, as well as having a content of up to about 15% adenosine (A) or preferably no adenosine content Obtaining oligonucleotides (oligonucleotides) that are antisense to a target selected from a group consisting of genomic and mRNA side regions selected from the group consisting of sites, and all mRNAs that encode polypeptides related to a preselected disease or condition and ; Selecting an oligo that significantly inhibits or eliminates expression of a polypeptide by mRNA during in vitro cross-linking with respect to a target mRNA among the oligos; Administering to the subject an amount of selected oligo that is effective for crossbreeding to the target mRNA; And evaluating the function of the subject related to the disease or condition before and after the oligo administration;n n n At this time, if the value of the function is 70% or more, the correlation is positive; if it is 40 to 70%, it is potentially positive; if it is 30% or less, the correlation is negative. To announce. The method of the present invention preferably provides the agent with direct access to the lungs by administering oligo into the subject's respiratory tract when validating the location where the target is located, i.e. malignant and other targets related to lung and respiratory function. . Alternatively, such deadenosine oligos may be delivered directly to the CNS or other organs, tissues and organ systems via known delivery formulations. |
| priorityDate | 1999-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2246.